Resources
News

Verrill Dana Welcomes Health Care Attorney Rachel Weisblatt

October 3, 2017 Press Releases

(October 3, 2017) – Verrill Dana is pleased to welcome health care attorney Rachel Weisblatt to the firm's Boston, Massachusetts office.

As a member of Verrill Dana's Health Care Group, Weisblatt's practice will focus on a wide variety of transactional, regulatory and litigation matters.

Previously, Weisblatt worked as an associate in the Public Finance Group of Mintz Levin. While there, she also served as bond counsel, underwriter's counsel and borrower's counsel for tax-exempt and taxable financings related to health care, housing, higher education and economic development, with a focus on 501(c)(3) health care financings.

Weisblatt received her law degree from Boston College Law School and earned her bachelor's degree from McGill University. While in law school, she served as a regulatory practice extern at the Massachusetts Health Policy Commission and interned at the Massachusetts Attorney General's Office in the Health Care Division. She also served as a Staff Writer for the Boston College Law Review.

About Verrill Dana's Health Care Group: Verrill Dana's Health Care Group serves a wide variety of organizations in the healthcare industry and related professions with respect to a wide range of matters including academic and biomedical research, accountable care organizations and managed care, eHealth and health information technology, HIPAA/HITECH privacy and security, Medicare/Medicaid and third-party reimbursement, mergers and acquisitions, and regulatory compliance. Learn more about the group at www.verrilldana.com/healthcare.

Firm Highlights

Publication/Podcast

“If I've told you once, I've told you eight times…” HHS OIG Issues Another Audit Report on Hospitals’ Failure to Report Credits for Explanted Cardiac Devices and Lays the Groundwork Collection of Overpayments

Publication/Podcast

Fraud and Abuse Investigations Handbook for the Health Care Industry, Second Edition.

Health care attorney Paul Shaw co-authored Fraud and Abuse Investigations Handbook for the Health Care Industry, Second Edition with Robert Griffith, published by the American Health Law Association (AHLA). Paul and Robert provide legal...

Publication/Podcast

340B Providers Get Partial Relief from New Dispute Resolution Regulation

1. 340B ADR Process Established At long last, more than ten years after Congress directed it to do so, HHS has finalized an alternative dispute resolution (“ADR”) process for both providers and pharmaceutical manufacturers...

Publication/Podcast

Massachusetts Health Care Bill Makes Several Significant Changes

While you were celebrating the New Year, Governor Baker signed Chapter 260 of the Acts of 2020, an “Act promoting a resilient health care system that puts patients first,” the result of the Legislature’s...

Publication/Podcast

HHS Confirms Providers’ Right to 340B Discount Pricing for Contract Pharmacies

As a holiday gift to providers, the U.S. Department of Health and Human Services (HHS) General Counsel recently issued a strongly worded Advisory Opinion indicating that federal law requires drug manufacturers to deliver covered...

News

Verrill Welcomes Jeffrey A. Smagula, Experienced Health Care and Life Sciences Attorney, Former Health Plan Compliance Executive

(May 12, 2021) – Verrill is pleased to welcome Jeffrey A. Smagula to the firm’s Boston office as Counsel in its nationally recognized Health Care & Life Sciences Group. Jeff Smagula brings to Verrill...

Publication/Podcast

Hospital Price Transparency Rule: Full Steam Ahead

Neither COVID-19 nor continued legal challenges appear likely to derail the Centers for Medicare & Medicaid Services ( CMS) Hospital Price Transparency Rule from going into effect on January 1, 2021. Hospitals therefore should...

Publication/Podcast

The Regulatory Sprint is Over - What’s at the Finish Line Under the New Stark and AKS Final Rules?

The U.S. Department of Health and Human Services (HHS) completed its “Regulatory Sprint” by finalizing changes to regulations pertaining to two federal fraud and abuse laws. On December 2, 2020, the Centers for Medicare...

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Contact Verrill at (855) 307 0700